Aclarion Announces Updated Product Release That Expands MRI Scanner Access For Nociscan Solution
Portfolio Pulse from Benzinga Newsdesk
Aclarion, Inc. (NASDAQ: ACON, ACONW) has announced the release of Nociscan 2.6, which expands the compatibility of its augmented intelligence platform to additional MRI scanners beyond Siemens. This development is expected to increase access to Nociscan for healthcare providers and patients globally, addressing chronic low back pain which affects approximately 266 million people. The company aims to make Nociscan the standard tool for diagnosing and treating chronic low back pain.
January 17, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclarion's release of Nociscan 2.6 could lead to increased adoption and sales, as it now supports a wider range of MRI scanners, potentially boosting ACON's market presence and revenue.
The release of Nociscan 2.6 is a significant product update for Aclarion, expanding its market potential by making the platform compatible with more MRI scanners. This could lead to increased usage by healthcare providers, driving up sales and potentially impacting ACON's stock price positively in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100